Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: Nephros develops hemodiafiltration (HDF) products for End Stage Renal Disease (ESRD) and water filtration systems (Dual Stage Ultrafilter). The company is a smaller reporting company and was delisted from the American Stock Exchange (AMEX) in January 2009, now trading on the OTC Bulletin Board.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 | Balance Sheet (Sep 30, 2009) |
|---|---|---|---|
| Product Revenues | $711,000 | $1,869,000 | - |
| Cost of Goods Sold | $463,000 | $1,251,000 | - |
| Gross Margin | $248,000 (35%) | $618,000 (33%) | - |
| Net Loss | $(395,000) | $(1,543,000) | - |
| Cash and Equivalents | - | - | $1,795,000 |
| Total Assets | - | - | $3,279,000 |
| Total Liabilities | - | - | $867,000 |
| Stockholders' Equity | - | - | $2,412,000 |
| Net Cash Used in Operations | - | $(1,870,000) | - |
Material Changes vs. Prior Period
- Revenue Growth: Product revenues increased 81% year-over-year for the nine months ended September 30, 2009 ($1.87M vs. $1.03M). This was driven by a $684,000 increase in military project revenue and $190,000 in water filter sales, partially offset by a decrease in European blood filter sales.
- Expense Reduction: Operating expenses decreased significantly due to resource conservation. Research and Development (R&D) expenses dropped 90% ($212k vs. $2.07M) primarily due to the absence of clinical trials in the current period. Selling, General, and Administrative (SG&A) expenses fell 45% ($2.09M vs. $3.83M) due to reduced headcount and lower professional fees.
- Net Loss Improvement: Net loss for the nine months decreased to $1.54M from $5.43M in the prior year period, aided by reduced operating costs and the absence of auction rate security impairments recorded in 2008.
- Financing Activity: In July 2009, the company raised $1.251 million through a private placement of common stock and warrants to eight accredited investors.
Outlook, Risks, and Contingencies
- Going Concern: Management states that recurring losses and negative cash flows raise substantial doubt about the company's ability to continue as a going concern. Additional funding is required before the end of 2010 to sustain operations.
- Regulatory Status: The FDA has not yet rendered a decision on the 510(k) application for the OLpur H2H module and MD 220 filter, though the company received approval for the DSU water filter for dialysis clinics in July 2009.
- Legal Proceedings:
- A former French employee was awarded 11,707 Euro (approx. $18,000) in back wages; an accrual has been recorded.
- A former U.S. employee claim was settled for approximately $11,000; an accrual of $6,000 was recorded.
- A third-party claim regarding the cancellation of an Auction Rate Securities transaction in 2008 is pending FINRA arbitration (scheduled for March 2010). No specific damages are identified, and the company denies liability.
- Capital Structure: As of November 11, 2009, 41,604,798 shares of common stock were outstanding. The company has significant outstanding warrants (approx. 8.2 million shares) with exercise prices ranging from $0.706 to $1.12.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $1.8M cash balance against the stated need for additional funding before the end of 2010.
- Revenue Concentration: Note that two customers accounted for 87% of sales in the first nine months of 2009 (45% and 42%).
- FDA Approval Timeline: Monitor the status of the pending 510(k) application for the OLpur H2H and MD 220 filter, which is critical for U.S. market expansion.
- Legal Exposure: Track the outcome of the FINRA arbitration regarding the 2008 Auction Rate Securities transaction.
- Dilution Risk: Assess the potential dilution from the 8.2 million outstanding warrants and the recent private placement.